Show simple item record

Phase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors.

dc.contributor.authorZubairi, I
dc.contributor.authorDean, Emma J
dc.contributor.authorMolife, L
dc.contributor.authorRanson, Malcolm R
dc.contributor.authorEl-Khouly, F
dc.contributor.authorSavulsky, C
dc.contributor.authorReyderman, L
dc.contributor.authorJia, Y
dc.contributor.authorHutton, E
dc.contributor.authorMorrison, R
dc.contributor.authorSweeting, L
dc.contributor.authorGreystoke, A
dc.contributor.authorBarriuso, J
dc.contributor.authorKristeleit, R
dc.contributor.authorEvans, T
dc.date.accessioned2017-08-16T08:41:34Z
dc.date.available2017-08-16T08:41:34Z
dc.date.issued2017
dc.identifier.citationPhase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors. 2017, 40:206-206 Oncol Res Treaten
dc.identifier.urihttp://hdl.handle.net/10541/620504
dc.language.isoenen
dc.titlePhase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentBeatson West Scotland Cancer Center, Glasgow, Lanark, Scotlanden
dc.identifier.journalOncology Research and Treatmenten


This item appears in the following Collection(s)

Show simple item record